PHOENIX Pharma Belgium

Active

Public limited companyfounded 1983active for 42 yearsEmile Vanderveldelaan 82, 1200 Sint-Lambrechts-Woluwe, BelgiumKBO/BCE: BE 0425.353.116

Summary

PHOENIX Pharma Belgium has been active since 1983 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €46.5m and a net result of €3.8m. Equity is growing by about 5.1% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.5% (low).

Risk analysisFollow Report Compare

PHOENIX Pharma BelgiumActiveChecked score 79/100

Risk analysis Report Compare

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

NACE 21201Wholesale of pharmaceutical and medical goods NACE 46460

Largest company by equity in Sint-Lambrechts-Woluwe, Manufacturing sector7 sites

Size

€1.33bnturnover 2026

Staff: 496.7 FTE
Equity: €46.5m
Profit: €3.8m

Financial health

79 Excellent Checked score 2026

Bankruptcy probabilitywithin 12 months: 0.5%

Structure

Parent: PHOENIX Belgium · 100%

Arnaud BerkenDirector
Philippe LacroixDirector

Auditor: Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises BV/SRL2026 accounts 67 days early15 of 46 deeds summarised

Why 79raises riskLiquidity: current ratio 1.22, cash €56,425Equity €46.5m (19.8% of total assets)7 establishment unitslowers riskFounded in 1983Show the evidence

Checked score

Score 2026

79 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 24% of its sector peers (NACE 21)

Every signal that counts is listed under Signals.

Financial strength · tick = 2025

Weak

Solvency 45+1

equity 19.8% of total assets

Liquidity 8+1

short-term debt 77.9% · cash 0.0%

Profitability 55+1

return on assets 1.6%

Bankruptcy probability, 12 months

0.5% Low

0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (16 companies, NACE 21, large)

Last 24 months 11-2024: 1.3% 12-2024: 1.7%▲ +0.4 percentage points vs 11-2024 01-2025: 2.7%▲ +1.0 percentage point vs 12-2024 02-2025: 2.7%● unchanged vs 01-2025 03-2025: 2.8%▲ +0.1 percentage points vs 02-2025 04-2025: 3.8%▲ +1.0 percentage point vs 03-2025highest value 05-2025: 3.8%● unchanged vs 04-2025highest value 06-2025: 3.8%● unchanged vs 05-2025highest value 07-2025: 3.4%▼ -0.4 percentage points vs 06-2025 08-2025: 0.5%▼ -2.9 percentage points vs 07-2025 09-2025: 0.5%● unchanged vs 08-2025 10-2025: 0.5%● unchanged vs 09-2025 11-2025: 0.5%● unchanged vs 10-2025 12-2025: 0.5%● unchanged vs 11-2025 01-2026: 0.5%● unchanged vs 12-2025 02-2026: 0.5%● unchanged vs 01-2026 03-2026: 0.5%● unchanged vs 02-2026lowest value 04-2026: 0.5%● unchanged vs 03-2026 05-2026: 0.5%● unchanged vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.5%● unchanged vs 06-2026 08-2026: 0.5%● unchanged vs 07-2026 09-2026: 0.5%● unchanged vs 08-2026 10-2026: 0.5%● unchanged vs 09-2026

Credit of up to €3,650,000 on 30-day terms is acceptable

Liquidity tight (current ratio 1.22, compared with 1.2 in 2025, below the usual 1.5; short-term debt: 77.9% and cash: 0% of total assets), and 80.2% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21): better than 12% on solvency, 7% on liquidity, 24% on profitability and 53% on growth.

The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: current ratio 1.22, cash €56,425

NBB · annual accounts

Equity €46.5m (19.8% of total assets)

NBB · annual accounts

Founded in 1983

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

7 establishment units

KBO · seat and establishments

Latest accounts filed on time

The financial year that closed on 31-01-2026 was due by 31-08-2026 and was filed on 25-06-2026, 67 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2026

67 days early

2025

55 days early

2024

58 days early

2023

20 days early

2022

24 days early

2021

44 days late

2020

23 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 29 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-01-2027 and is due by 31-08-2027. Nothing is late today. The company usually files around 5 July (3 of the last 3 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

30-10-2026 today31-01-2027 year end31-08-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

03-09-2026 Reappointment: Arnaud Berken (director)Gazette deed
25-06-2026 Annual accounts filedfinancial year 2026 · full…
31-01-2026 Highest result from 2019 to 2026net €3.8m ▲115%

Key points

Positive: Result rose in 2026from €1.8m to €3.8m ▲ 115% View
Positive: Largest company by equity in Sint-Lambrechts-Woluwe, Manufacturing sectorin the Checked rankings No. 1 View
Controlled by PHOENIX Belgiumultimately: PHOENIX Pharmahandel GmbH &… 100% View
Positive: 3 years of growth in a rowturnover 2026: €1.33bn 3 years View
Positive: Filed on time since financial year 2022accounts within the deadline every year 5 years View

By topic

Financials

Financial year: 2026
Turnover: €1.33bn
Profit: €3.8m
Solvency: 19.8%

Turnover▲ 7.3%

Net result

20192026

Go to Financials

Board & ownership

Board: 2 members
Parent: PHOENIX Belgium · 100%
Auditor: Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises BV/SRL

Arnaud BerkenDirector
Philippe LacroixDirector

Go to Board & ownership

Network & group

Group: PHOENIX Pharmahandel GmbH &…

Go to Network & group

Timeline

Events: 55
Since: 1985
Next accounts: by 31-08-2027

15-07-2025Resignation: Deloitte Bedrijfsrevisoren/Réviseurs d'entreprises BV SRL (statutory…
07-07-2025Annual accounts filed
25-02-2025Amendment of the articles · Name

Go to Timeline

Company details

Sites: 7

Legal form: Public limited company
Activity: Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Founded: 28-12-1983
Year ends: 31-01
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 4

Annual meeting: Third Wednesday of June at 14:00

Go to Articles of association

Key facts about PHOENIX Pharma Belgium

What is the company number of PHOENIX Pharma Belgium?: 0425.353.116. In Belgium the VAT number is the company number with BE in front: BE 0425.353.116.
Where is PHOENIX Pharma Belgium based?: The registered office is at Emile Vanderveldelaan 82, 1200 Sint-Lambrechts-Woluwe.Company details
What does PHOENIX Pharma Belgium do?: According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of PHOENIX Pharma Belgium?: Public limited company (NV).
When was PHOENIX Pharma Belgium founded?: On 28-12-1983.
Is PHOENIX Pharma Belgium still active?: Yes, PHOENIX Pharma Belgium is an active enterprise in the KBO register.
How many employees does PHOENIX Pharma Belgium have?: On average 496.7 full-time equivalents in financial year 2026, according to the filed annual accounts.Financials
What is the turnover of PHOENIX Pharma Belgium?: €1.33bn in financial year 2026, according to the filed annual accounts.
Is PHOENIX Pharma Belgium profitable?: In financial year 2026, PHOENIX Pharma Belgium made a profit of €3.8m.
Where can I find the annual accounts of PHOENIX Pharma Belgium?: PHOENIX Pharma Belgium filed 43 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of PHOENIX Pharma Belgium due?: By 31-08-2027, for financial year 2027.Timeline